Dinitroazetidines are a novel class of anticancer agents and hypoxia-activated radiation sensitizers developed from highly energetic materials

Cancer Research

Volumn 72, Issue 10, 2012, Pages 2600-2608

  Ning, Shoucheng ^a   Bednarski, Mark ^b   Oronsky, Bryan ^c   Scicinski, Jan ^c   Saul, Gordon ^c   Knox, Susan J ^a  

^a STANFORD UNIVERSITY MEDICAL CENTER   (United States)

^b STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c RadioRx Inc   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

1 BROMOACETYL 3,3 DINITROAZETIDINE; ANTINEOPLASTIC AGENT; CISPLATIN; FREE RADICAL; REACTIVE OXYGEN METABOLITE; TIRAPAZAMINE; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ANTIPROLIFERATIVE ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CANCER CHEMOTHERAPY; CANCER INHIBITION; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG CYTOTOXICITY; DRUG EFFICACY; DRUG MECHANISM; DRUG STRUCTURE; DRUG TOLERABILITY; HUMAN; HUMAN CELL; MALE; MOUSE; NONHUMAN; OXIDATION REDUCTION STATE; PRIORITY JOURNAL; RADIOSENSITIZATION; SQUAMOUS CELL CARCINOMA; TUMOR BLOOD FLOW;

ANIMALS; ANTINEOPLASTIC AGENTS; AZETIDINES; CARCINOMA, SQUAMOUS CELL; CELL HYPOXIA; CELL LINE, TUMOR; COMBINED MODALITY THERAPY; DRUG EVALUATION, PRECLINICAL; FREE RADICALS; HUMANS; MALE; MICE; MICE, INBRED C3H; NEOPLASMS; NITRO COMPOUNDS; RADIATION-SENSITIZING AGENTS;

EID: 84861150389     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-11-2303     Document Type: Article

References (28)

1. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Murray T, Thun MJ. Cancer statistics, 2008. CA Cancer J Clin 2008;58:71-96. (Pubitemid 351521864)
2. Bucci MK, Bevan A, Roach M. Advances in radiation therapy: conventional to 3D, to IMRT, to 4D, and beyond. CA Cancer J Clin 2005;55:117-34. (Pubitemid 40372906)
3. Harrison LB, Chadha M, Hill RJ, Hu K, Shasha D. Impact of tumor hypoxia and anemia on radiation therapy outcomes. Oncologist 2002;7:492-508. (Pubitemid 36008998)
4. Wendt TG, Grabenbauer GG, Rodel CM, Thiel HJ, Aydin H, Rohloff R, et al. Simultaneous radiochemotherapy versus radiotherapy alone in advanced head and neck cancer: a randomized multicenter study. J Clin Oncol 1998;16:1318-24. (Pubitemid 28175746)
5. Churchill-Davidson I. The oxygen effect in radiotherapy: historical review. Front Radiat Ther Oncol 1968;1:1-15.
6. Wasserman TH, Stetz J, Phillips TL. Radiation therapy oncology group clinical trials with misonidazole. Cancer 1981;47:2382-90. (Pubitemid 11127626)
7. Brown JM, Yu N, Brown DM, Lee WW. SR-2508: A 2-nitroimidazole amide which should be superior to misonidazole as a radiosensitizer for clinical use. Int J Radiat Oncol Biol Phys 1981;7:695-703. (Pubitemid 11060951)
8. Bump EA, Yu N, Brown JM. Radiosensitization of hypoxic tumor cells by depletion of intracellular glutathione. Science 1982;217:544-5. (Pubitemid 12099338)
9. Yu N, Brown JM. Depletion of glutathione in vivo as a method of improving the therapeutic ratio of misonidazole and SR 2508. Int J Radiat Oncol Biol Phys 1984;10:1265-9. (Pubitemid 14029875)
10. Mitchell JB, Russo A, Kinsella TJ, Glatstein E. The use of non-hypoxic cell sensitizers in radiobiology and radiotherapy. Int J Radiat Oncol Biol Phys 1986;12:1513-8. (Pubitemid 16030651)
11. Rosenthal DI, Nurenberg P, Becerra CR, Frenkel EP, Carbone DP, Lum BL, et al. A phase I single-dose trial of gadolinium texaphyrin (Gd-Tex), a tumor selective radiation sensitizer detectable by magnetic resonance imaging. Clin Cancer Res 1999;5:739-45. (Pubitemid 29180823)
12. McKeown SR, Cowen RL, Williams KJ. Bioreductive drugs: from concept to clinic. Clin Oncol (R Coll Radiol) 2007;19:427-42. (Pubitemid 46995614)
13. Kaanders JH, Bussink J, van der Kogel AJ. Clinical studies of hypoxia modification in radiotherapy. Semin Radiat Oncol 2004;14:233-40. (Pubitemid 38903227)
14. Fried LE, Manaa MR, Pagoria PF, Simpson RL. Design and synthesis of energetic materials. Annu Rev Mater Res 2001;31:291-321. (Pubitemid 33073852)
15. Knox SJ, Cannizzo L, Warner K, Wardle R, Velarde S, Ning S, inventors; RadioRx, Inc., Alliant Techsystems Inc., assignees. Cyclic nitro compounds, pharmaceutical compositions thereof and uses thereof. United States patent US7507842B2. 2009 Mar 24.
16. Straessler NA, Lesley MW, Cannizzo LF. Development of a safe and efficient two-step synthesis for preparing 1-bromoacetyl-3,3-dinitroazetidine, a novel clinical anti-cancer candidate. Org Process Res Dev 2012;16:512-7.
17. Ning S, Shui CX, Khan WB, Knox SJ. Effects of keratinocyte growth factor on the proliferation and radiation survival of human epithelial cell carcinoma cell lines in vitro and in vivo. Int J Radiat Oncol Biol Phys 1998;40:177-87. (Pubitemid 28027584)
18. Ning S, Knox SJ. Increased cure rate of glioblastoma using concurrent therapy with high dose radiation and arsenic trioxide. Int J Radiat Oncol Biol Phys 2004;60:197-203. (Pubitemid 39165485)
19. Ning S, Tian J, Marshall DJ, Knox SJ. Anti-av integrin monoclonal antibody intetumumab enhances the efficacy of radiation therapy and reduces metastasis of human cancer xenografts in nude rats. Cancer Res 2010;70:7591-9.
20. Khan WB, Shui C, Ning S, Knox SJ. Enhancement of murine intestinal stem cell survival after irradiation by keratinocyte growth factor. Radiat Res 1997;148:248-53. (Pubitemid 27374102)
21. Chapman JD. Hypoxic sensitizers - implications for radiation therapy. N Engl J Med 1979;301:1429-32. (Pubitemid 10199238)
22. Brown JM. SR 4233 (tirapazamine): a new anticancer drug exploiting hypoxia in solid tumours. Br J Cancer 1993;67:1163-70.
23. Scicinski J, Oronsky B, Fitch WL, Taylor M, Luo G, Musick T, et al. Disposition of 14C-RRx-001 in rats after a single intravenous administration and in blood from rats, dogs, monkeys and humans [abstract]. In: Proceedings of the 17th North American ISSX Meeting; 2011 Oct; Atlanta, GA. Abstract nr P81.
24. Sikder N, Sikder AK, Bulakh NR, Gandhe BR. 1,3,3-Trinitroazetidine (TNAZ), a melt-cast explosive: synthesis, characterization and thermal behaviour. J Hazard Mater 2004;113:35-43. (Pubitemid 41379424)
25. Lee DJ, Cosmatos D, Marcial VA, Fu KK, Rotman M, Cooper JS, et al. Results of an RTOG phase III trial (RTOG 85-27) comparing radiotherapy plus etanidazole with radiotherapy alone for locally advanced head and neck carcinomas. Int J Radiat Oncol Biol Phys 1995;32:567-76.
26. Reddy SB, Williamson SK. Tirapazamine: a novel agent targeting hypoxic tumor cells. Expert Opin Investig Drugs 2009;18:77-87.
27. Lorch JH, Posner MR, Wirth LJ, Haddad RI. Induction chemotherapy in locally advanced head and neck cancer: a new standard of care? Hematol Oncol Clin North Am 2008;22:1155-63.
28. Wong G, Mehta MP. Combined chemoradiotherapy advances. Cancer Treat Res 2008;139:277-301.